- Amended Statement of Ownership: Solicitation (SC 14D9/A)
26 Juillet 2012 - 9:49PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14D-9
Solicitation/Recommendation Statement under Section 14(d)(4)
of the Securities Exchange Act of 1934
(Amendment No. 16)
HUMAN GENOME
SCIENCES, INC.
(Name of Subject Company)
HUMAN GENOME SCIENCES, INC.
(Name of Person Filing Statement)
Common Stock, $0.01 par value per share
(Title of Class of Securities)
444903108
(CUSIP Number of Class of Securities)
James H. Davis
Executive Vice President, General Counsel and Secretary
14200 Shady Grove Road
Rockville, Maryland 20850-7464
(301) 309-8504
(Name, address and telephone number of person authorized to receive notices
and communications on behalf of the person filing statement)
With copies to:
|
|
|
Michael P. Rogan
Marc S. Gerber
Skadden, Arps, Slate, Meagher & Flom
LLP
1440 New York Avenue, NW
Washington, D.C. 20005
(202) 371-7000
|
|
Robert W. Smith, Jr.
Jason C. Harmon
DLA Piper LLP (US)
6225 Smith Avenue
Baltimore, Maryland 21209
(410) 580-3000
|
¨
|
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
Introduction
This Amendment No. 16 to the Schedule 14D-9 (the Amendment) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended from time to time, the
Statement) originally filed by Human Genome Sciences, Inc., a Delaware corporation (HGS or the Company), with the Securities and Exchange Commission (the SEC) on May 17, 2012. Except as otherwise
set forth in this Amendment, the information set forth in the Statement remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment. Capitalized terms used but not defined herein have the meanings ascribed to
them in the Statement.
Item 8.
Additional Information
Item 8 of the Statement is hereby amended and supplemented by adding the following text as new paragraphs immediately following the
last paragraph under the heading Litigation:
With respect to the foregoing case,
David, et al. v. Human Genome Sciences, Inc., et al.
, C.A. No. 1:12-cv-00965, on July 26, 2012, the District Court denied plaintiffs motion for a temporary restraining order.
With respect to the foregoing case,
Markovic v. Human Genome Sciences, Inc., et al.
, Docket No. 366054-V, on
July 26, 2012, the Circuit Court heard oral arguments and denied plaintiffs motion for a temporary restraining order.
1
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
HUMAN GENOME SCIENCES, INC.
|
|
|
By:
|
|
/s/ James H. Davis
|
Name:
|
|
James H. Davis
|
Title:
|
|
Executive Vice President, General Counsel and Secretary
|
Dated: July 26, 2012
Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024